Literature DB >> 21575314

Delayed diagnosis of Kawasaki disease: risk factors and outcome of treatment.

R Sittiwangkul1, Y Pongprot, S Silvilairat, C Phornphutkul.   

Abstract

BACKGROUND: Kawasaki disease (KD) is associated with a high incidence of coronary artery aneurysms in untreated children. Treatment with intravenous immunoglobulin (IVIG) within the 1st 10 days of illness reduces by approximately fivefold the prevalence of coronary artery abnormalities (CAA). Data regarding delayed diagnosis of KD in Thailand have not been reported in the literature. AIMS: To determine the prevalence, risk factors and outcome of delayed diagnosis of KD in Thai patients.
METHODS: We retrospectively reviewed the medical records of patients at Chiang Mai University Hospital diagnosed as KD during 2000-2008. Patients were classified into two groups: Group I were diagnosed ≤10 days of fever and Group II were diagnosed >10 days of fever.
RESULTS: Of 170 patients, 150 were in Group I [mean (SD) fever 7 (1·45) d] and 20 (11·7%) in Group II [mean (SD) fever 15 (4) d]. There were no statistical differences between the two groups in age, gender, number of KD clinical manifestations or laboratory results, except that Group II were of lower weight (p = 0·01). Group II were younger (p = 0·09) and had more incomplete criteria (p = 0·09) but the differences were not statistically significant. Group II had a higher incidence of CAA (75% vs 19%) (p<0·001), more severe CAA and more resistant cases (31·2% vs 9·5%) (p = 0·04).
CONCLUSION: Patients with delayed diagnosis of KD have a higher risk of developing CAA and of a more severe outcome for coronary artery disease. Education is needed to make healthcare providers and physicians more aware of KD, especially in small children or those with incomplete KD.

Entities:  

Mesh:

Year:  2011        PMID: 21575314     DOI: 10.1179/1465328111Y.0000000005

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN: 0272-4936


  8 in total

1.  Application of prospective ECG-triggered dual-source CT coronary angiography for infants and children with coronary artery aneurysms due to Kawasaki disease.

Authors:  Y Duan; X Wang; Z Cheng; D Wu; L Wu
Journal:  Br J Radiol       Date:  2012-08-29       Impact factor: 3.039

2.  [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].

Authors:  Xin Wang; Si-Lin Pan; Zhan-Hui DU; Zhi-Xian Ji; Gang Luo; Hong-Xiao Sun; Shu-Jing Ma
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

3.  The Xi'an Experience of Kawasaki Disease - Lessons Learnt over 5 years.

Authors:  Fuyong Jiao; Xiaohua Yan; Xiaofang Wu
Journal:  Indian J Pediatr       Date:  2016-04-20       Impact factor: 1.967

4.  Effect of delayed diagnosis on disease course and management of Churg-Strauss syndrome: a retrospective study.

Authors:  Barbara Sokołowska; Wojciech Szczeklik; Lucyna Mastalerz; Paweł Kuczia; Michał Wodkowski; Edyta Stodółkiewicz; Karolina Macioł; Jacek Musiał
Journal:  Clin Rheumatol       Date:  2012-11-29       Impact factor: 2.980

5.  Kawasaki disease among Egyptian children: A case series.

Authors:  Tarek Hamed Attia; Saed M Morsy; Bashier A Hassan; Al Shymaa A Ali
Journal:  Glob Cardiol Sci Pract       Date:  2017-10-31

6.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

7.  Lipocalin-2-induced proliferative endoplasmic reticulum stress participates in Kawasaki disease-related pulmonary arterial abnormalities.

Authors:  Zhaoling Shi; Yue Yin; Chen Li; Hui Ding; Nan Mu; Yishi Wang; Shanshan Jin; Heng Ma; Manling Liu; Jie Zhou
Journal:  Sci China Life Sci       Date:  2020-09-09       Impact factor: 6.038

Review 8.  Kawasaki Disease: A Clinician's Update.

Authors:  Nathan Jamieson; Davinder Singh-Grewal
Journal:  Int J Pediatr       Date:  2013-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.